This is looking very good on the graph. We're up to .028 right now. Looks like something is up.
Posted by AtHomeDad on :
Beto, This is a slow mover. It just needs time, but I'll take sooner rather then later.
I normally HATE the word Diversity, but this Co. has good diversification. My bet is on the Pharm that will make this thing jump.
ABOUT US
DNAPrint™ genomics, Inc. is a cutting edge company. We are concentrating our efforts in four distinct areas; Pharmacogenomics, Forensics, Genotyping, and Consumer Products. Our aim is to continue to research and develop novel products and services in each of these market areas and to be a leader in genomic-based technologies.
The Company’s core patent applied for and proprietary technologies for efficiently targeting single nucleotide polymorphisms (“SNPs”) enable us to provide novel predictive genetic tests at a significant cost advantage over our competitors.
We have identified and applied for patenteds to cover the maps of certain SNPs that we believe have broad commercial applications. These commercially valuable SNPs are called Ancestry Informative Markers (“AIMs”) and are an integral part of our proprietary Admixture Mapping (“Mapping”) method. With our mapping, we leverage known statistical data about population structure to substantially reduce the number of SNPs analyzed and therefore more cost effectively identify genes responsible for certain traits. Our proprietary data and analytical resources for using AIMs are integral to our strategy of offering DNA tests that provide value in other ways too – from better study design using more traditional methods, and generating valuable predictive results, including a person’s physical characteristics, BioGeographical Ancestry (“BGA”), and predisposition to respond to certain pharmaceutical drugs.
WE ARE CURRENTLY FOCUSING OUR EFFORTS IN FOUR DISTINCT MARKETS:
Consumer DNA Products Market - There is an established market of consumers who recreationally research their genealogy and ancestral origin but only recently has it become possible to apply modern advances in genome technology to this endeavor. AncestryByDNA, the flagship product of our Genealogy line of services and products, now makes it affordable for the general public to use the power of genomics to discover their genetic ancestry. This is a great tool for individuals or groups interested in more deeply and scientifically exploring their genetic heritage and often customers are able to learn something about their lineage that is several thousand years old. By submitting a DNA sample to our lab, customers receive an impressive and detailed analysis of their BioGeographical origins
Forensics DNA Testing Market - Testing DNA to create a physical description from crime scene DNA and provide a photo database array of representative closely matching the analyzed DNA allows detectives a means of describing ‘persons of interest’. This presumptive test method is a new market based on evolving DNAPrint genomics technologies. Common hereditary traits such as skin pigmentation, eye color, hair color, facial geometry and even height can be predicted through analysis of DNA sequences. This can be done indirectly, through an extensive knowledge of ancestry admixture or for certain genetic traits, directly through knowledge of the underlying genes. At DNAPrint™ we use both methods. Our goal is to continue to lead the field of forensic presumptive testing using our DNAWitness line of products and services.
Pharmacogenomics Market - The testing of individuals to predict their genetic predisposition to drug response is known as pharmacogenomics. Pharmacogenomics enables physicians to tailor drug therapies (formulation and dosage) for individuals based on their genetic composition, increasing rates of therapeutic success and decreasing rates of adverse side effects. Drug discovery companies are beginning to use pharmacogenomics technologies to develop drugs that are suitable for subpopulations based upon their genetic composition. We at DNAPrint believe that as doctors and health care providers have been reporting for thousands of years; that different peoples from different countries have variable responses to medications is reason enough for us to explore this realm of medicine. We hope to be able to help predict whether a woman taking a chemotherapy agent for a cancer will respond favorably to a drug. We also will apply our technology to our own therapeutics, such as PT-401 a ‘super EPO’ and help improve the efficacy of the drug therapy going into clinical evaluation as well as helping to improve and maintain patient response efficacy after the drug is approved. Pharmaceutical and pharmaceutical diagnostics are important cornerstones for our future value to our shareholders. We believe individualized medicine, while still some years away, will be here to stay, especially now that the U.S. FDA has written about pharmacogenomics. view PDF
Contract Service Outsourcing Market - DNAPrint™ provides universities and drug discovery companies with genotyping services. The service provides our clients with the ability to screen efficiently and effectively for genes that may be responsible for certain human traits and/or disease states.
We see exciting growth opportunity in these markets to introduce and sell our novel products and services. Few Universities and Medical centers can afford to invest millions of dollars and spend years of research time developing a methodology that DNAPrint can make readily available to them at a competitive and economical rate. We continue to improve our laboratory’s throughput capacity and lowered our per genotype costs on our Ultra High Throughput SNP machine.
Posted by AtHomeDad on :
more PR on R&D
Updated:2006-03-03 07:41:53 DNAPrint Genomics Enters Into Sponsored Research Agreement With Massachusetts College of Pharmacy and Health Sciences Market Wire SARASOTA, FL -- (MARKET WIRE) -- 03/03/06 -- DNAPrint Genomics, Inc. (OTC BB: DNAG) today announced that it has entered into a Research Sponsorship Agreement with the Massachusetts College of Pharmacy and Health Sciences for the potential development of Ritalin(TM)-like compounds as possible medications for drug abuse, attention deficit hyperactivity disorder (ADHD) and depression. According to the National Institute of Mental Health, between 3 and 5 percent of children have ADHD, or approximately 2 million children in the United States.
The research will be conducted under the supervision of Dr. Mark Froimowitz, a researcher at the Boston-based College, who recently licensed the compounds to DNAPrint Genomics. The compounds are analogs of Ritalin, a well-known drug used for treatment of ADHD and designed specifically to take effect slowly but last longer, thus reducing their potential for abuse and a patient's required daily dosage.
DNAPrint Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D., who also heads the clinical development for the Company's newly formed subsidiary, DNAPrint Pharmaceuticals, Inc., said his staff and Dr. Froimowitz will be working together closely to develop "theranostic" test/drug combinations based on the compounds designed to ensure that patients receive the appropriate medicine and proper dosage based on a patient's genetic constitution. Theranostic test/drug combinations are designed to reduce efficacy and side effects problems associated with conventional drug treatments.
"These Ritalin-like compounds present an ideal opportunity for our goal to develop products for personalized medicine," Dr. Gomez stated. "DNAPrint's capabilities in genomics and the College's expertise in pharmaceuticals represent a powerful synergy in the field of theranostic drug research."
According to Dr. Froimowitz, Research Professor of Chemistry at the Massachusetts College of Pharmacy and Health Sciences, "These compounds have a number of desirable properties and possible therapeutic indications. The possibility of linking their clinical use to patient genomics represents the future of drug development."
"Many researchers believe that a strong link exists among drug addiction, ADHD and depression. There is a tremendous variation, however, across patient populations, with respect to drug response for the therapies used to treat these disorders," said Richard Gabriel, Chief Executive Officer and President of DNAPrint Genomics, Inc. "In fact, the National Institute of Drug Abuse has selected one of Dr. Froimowitz's compounds for their pre-clinical drug addiction development program. We will be supplying purified compounds to NIDA for further development."
Posted by ehya on :
Good post, im definitely hangin on this one, great potential
Posted by ehya on :
What keeps a stock like DNAG from breaking out to a higher pps on such large volume? Anyone that has ideas on this, I would love to hear them. Thanks
Posted by ehya on :
Market Pulse Breaking News Alert for Tuesday, March 7, 2006: DNAG -- DNAPrint Genomics Scientist to Co-Chair Discussion on "Genetic Testing" at the American Association of Physical Anthropologists Annual Meeting!
By Market Wire Last Update: 3/7/2006 8:50:02 AM Data provided by
ATLANTA, GA,, Mar 07, 2006 (MARKET WIRE via COMTEX) -- Market Pulse News Alert for this AM, Stocks to Watch are: DNAPrint Genomics, Inc. (DNAG), Ivanhoe Energy Inc. (IVAN), Finisar Corp. (FNSR) and Quest Communications International Inc. (Q).
Investors need to be watching DNAPrint Genomics, Inc. (DNAG) this AM! DNAPrint is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology, and consumer genetic tests. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWitness(TM), RETINOME(TM) (a predictive test for inferring eye color from a DNA sample), ANCESTRYbyDNA(TM), and EURO-DNA(TM). DNAPrint's management sees exciting growth opportunity in these markets to introduce and sell their novel products and services. DNAG has had several excellent news announcements out lately and one again before today's opening bell announcing that their scientist Dr. Ripan Malhi will co-chair a discussion on genetic testing at the American Association of Physical Anthropologists annual meeting! Investors should be watching this one closely!
DNAPrint Genomics, Inc. (DNAG) today announced that Dr. Ripan Malhi will co-chair a symposium of 14 scientists and business persons for a discussion of ethical and sociopolitical issues surrounding consumer genetic testing as part of the 75th annual meeting of the American Association of Physical Anthropologists in Anchorage, Alaska. Dr. Malhi is the Senior Research Director of Trace Genetics, Inc., the Company's wholly owned subsidiary. The four-day meeting, which begins Wednesday, March 8, features several symposiums and poster discussions. This symposium focuses on the interpretation of genetic test results and the public's understanding of race, ethnicity, human genetic variation and evolutionary history of the human species.
"The purpose of this symposium is to have a rigorous discussion of lineage based and whole genome tests exploring the anthropological, biomedical, and societal applications of genetic ancestry testing," explains Dr. Malhi. "It should be a lively discussion. We have purposefully brought together competent spokespersons with diverse perspectives. This will be an opportunity for opinions to be expressed and challenged and, ideally, allow the group as a whole to resolve issues in a direct and productive manner."
The symposium brings together scientists and experts from academia and private enterprise in an effort to build a consensus about how the public might best use genetic testing to understand their own ancestry within a valid scientific framework. Recent television specials and news publications have spurred public interest in genetic testing, resulting in the recent purchase by consumers of more than 150,000 genetic ancestry tests. The popularity of these genetic tests reflects a widespread interest by the public in using DNA technology to learn about family ancestry. Many anthropologists are concerned that the interpretation of the results of these tests may not give a complete and accurate picture of an individual's personal genetic history.
"Until recently the only way genealogists could determine their ancestors' origins was through records and oral history that traced ancestors as far back as the documentation existed. Now, genetic tests can reveal remote anthropological ancestry and suggest proportions of various ethnic and geographical origins such as Native American ancestry, in a given person's heritage. Genealogists should use the information for the test's intended purpose as one piece of a large and complex puzzle and avoid prejudice based on what they hoped they would find," commented Dr. Tony Frudakis, Chief Scientific Officer for DNAPrint Genomics.
The symposium is a featured event of the annual meeting, and is scheduled to be the cover article of the Saturday, March 11, edition of New Scientist magazine.
Posted by ehya on :
Attention in particular to the last line of that article...
"The symposium is a featured event of the annual meeting, and is scheduled to be the cover article of the Saturday, March 11, edition of New Scientist magazine."
Posted by JimSC on :
pps is controlled by the MMs. They have their time table for each stock. Good news will not work if they are not ready to run it. CLBE, JKRI, and GLIF got a run without any PR. XKEM got a pull-down on news. AMEP and DNAG are waiting for their turns. So just be patient, when the MMs are ready, it will run. Trust the MMs' ability to pump.
Posted by JimSC on :
DNAG: the MMs have collected tons of cheap shares, so must we.
Posted by ehya on :
Great great reply JimSC, thankyou
Posted by ehya on :
Harvard University Receives Notice of Allowance on Diagnostic Patent Claims Licensed to DNAPrint Genomics, Inc. Thursday March 9, 7:00 am ET
SARASOTA, FL--(MARKET WIRE)--Mar 9, 2006 -- DNAPrint Genomics, Inc. (OTC BB:DNAG.OB - News) today announced that Harvard University has received formal Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for 20 claims that cover diagnostic uses of a novel marker for diabetes licensed by the Company. DNAPrint entered into an agreement with Harvard in January 2006 to sponsor continued research based on the marker, CD59, in the Harvard Medical School laboratory of Dr. Jose Halperin, a named inventor of the allowed claims. These claims, once issued, will provide Harvard additional intellectual property protection to support the development and commercialization by DNAPrint of new diagnostic tests to better define and manage diabetes more effectively.
The studies conducted by Dr. Halperin and his Harvard Medical School colleagues indicate that CD59 becomes inactivated in the presence of high blood glucose levels observed in patients with diabetes, and thus does not function normally to protect blood vessel walls from inflammatory damage. This leads to the obstruction of the many small vessels that provide critical nutrients and oxygen to organs and tissues. The common vascular disease complications suffered by individuals with diabetes -- nephropathy, retinopathy, neuropathy and atherosclerotic heart disease -- are all believed to be caused by this vascular obstruction and destruction. A test to detect CD59 in its glycated, inactive form would be a specific warning that the patient has had poor glucose control and that vascular complications are developing even before clinical symptoms show irreversible tissue and organ damage.
"Microvascular damage in the kidney, blindness due to damage of blood vessels in the retina, and tissue death in the extremities due to damage of the nerves and obstruction of the arteries are major reasons why medical costs are so high for patients with diabetes as well as causing unfortunate suffering for this group of patients of all ages," commented DNAPrint Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D., who also heads the clinical development for the Company's newly formed subsidiary, DNAPrint Pharmaceuticals, Inc. "Today, there is no test that directly measures or monitors the progressive damage caused by the intermittent high sugar or glucose levels experienced by even well-controlled diabetes patients. Now we are able to move forward confidently with the development of our test, knowing that we have appropriate patent protection."
"Approval of the latest patent claims represents a milestone for Dr. Jose Halperin of Harvard Medical School and his team," commented DNA Print President and Chief Executive Officer Richard Gabriel. "According to the Center for Disease Control and Prevention, the total direct and indirect cost for both type 1 and type 2 diabetes in the United States in 2002 (four years ago) was $132 billion. Our goal is to try to help patients with diabetes understand their disease earlier, and with this knowledge, attempt to minimize their physical complications as well as reduce the associated expense to the U.S. healthcare system. We also know from physician reports that diabetes is expressed more in some patient population groups than others, so coupling our new CD59 diagnostic with our genetic ancestry information will be a valuable tool in developing and understanding the CD59 diagnostic," he concluded.
Details about the field-exclusive licensing agreement between DNAPrint Genomics, Inc. and Harvard University announced on January 26, 2006 can be found at:
DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation, to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Contact:
Company Contact: Richard Gabriel CEO and President (941) 366-3400
Ron Stabiner The Wall Street Group, Inc. (212) 888-4848
Source: DNAPrint Genomics, Inc.
Posted by JimSC on :
Up 2.5% with huge volume. L2 lineup is ready for a run. Watch it.
Posted by Johnwayne on :
JimSC- She's right at the pivot point of .0241 here I see some resistence at around .025 and more at .03. RSI looks good at 55 float 130m O/S 150m Level 2 looks good. How high do you think she'll blow? Do you see this as a quick popper or slow and steady?
Posted by JimSC on :
0.0242 X 0.0245
up 4.2%.
The MMs are ready to let her go.
Watch it.
Posted by Johnwayne on :
If it breaks .025 (Nite) it should cruise into .03 and that looks like the showdown right now because there isn't alot of resistance between .03 and .10. Would like to see a nice steady three day run on this one.
Posted by Johnwayne on :
She's through .025! Must have been a fake wall. Let's see if we can run it up to .03 now. Looks like MM's are setting up camp at .03 to try to cap it. 5mms at .03 ask.
Posted by Johnwayne on :
Wall at .026 held the first time. Let's see if we can get through it later today.
Posted by Forrestgump on :
I like the Chart...
Posted by Johnwayne on :
Alot of shares (500,000)traded between 11:30-12:00 at or above .026. Should make it a little easier to poke through if we get up that high again today.
Posted by ehya on :
Ask * .026 V 10.5M
Market Pulse Breaking News Alert for Thursday, March 9, 2006: DNAG -- Harvard University Receives Notice of Allowance on Diagnostic Patent Claims Licensed to DNAPrint Genomics, Inc.
Investors need to be watching DNAPrint Genomics, Inc. (OTC BB: DNAG) this AM! DNAPrint is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology, and consumer genetic tests. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWitness(TM), RETINOME(TM) (a predictive test for inferring eye color from a DNA sample), ANCESTRYbyDNA(TM), and EURO-DNA(TM). DNAPrint's management sees exciting growth opportunity in these markets to introduce and sell their novel products and services. DNAG has had several excellent news announcements out lately and one again before today's opening bell. DNAPrint today announced that Harvard University has received formal Notice of Allowance from the U. S. Patent and Trademark Office (USPTO) for 20 claims that cover diagnostic uses of a novel marker for diabetes licensed by the Company! Investors should be watching this one closely!
Posted by Johnwayne on :
Bid stacking up here 4 * .025 Nite(axe) at .026 on ask though
Posted by Johnwayne on :
Couldn't beat nite today. Nite finished at .0257 on ask. As usual I think if you watch Nite on level 2 you can figure out where the pps is going. Good news is we saw alot of buys at the .0257 price which will hopefully soften that up for tomorrow. Sorry if I'm annoying anyone by chattering so much. Pay no attention to me. Heck I probably don't know what I'm talking about anyway!
Posted by JimSC on :
Looks like the MMs intend to make DNAG run like IMNR, which jumped up 400% in 4 weeks after a few siwings. So, just be patient and hold your shares tight. IMO.
Posted by ehya on :
Keep talking John, I enjoy reading any insight or opinion you have. Who doesnt like to know what others are thinking?
Posted by djequipment on :
I have commented in one of the other threads. I flipped DNAG for over 100% on it's last run from .02 to .04+.
I've been holding for a while * .023, and I feel the rumblings a coming for some more DNAG $$$.
Posted by JimSC on :
Thanks to JohnWayne for sharing his DD with us.
Posted by Johnwayne on :
Thanks guys for your kind words. But it's only fair I let you know I am a newby so please do not rely on my limited insight and experiences to make any decisions. Hah Hah. I always wanted to say that. Good luck to all.
Posted by Johnwayne on :
Level 2 looking sweet right now!I do have 15 minute delay on mine but let's hope it holds up. bid - 5*.025 ask - 1*.0259 3*.026 (Nite)
500,000 buy pre-market!
Posted by Johnwayne on :
.0259 ask can't hold much longer. Alot of buys going through at .0259 bid is 4*.0255
Posted by Johnwayne on :
Volume slowed and bid is weakening. Looks like we are slowing down for now!!!!
Posted by Johnwayne on :
Spread has widened to put the brakes on this. Nobody selling at .0241 bid. A standoff!
Posted by ehya on :
Lunch
Posted by Johnwayne on :
Yeah lunch, as I bite into my 6 inch subway tuna sandwich, but now Nite is on the ask at .025. He will bottle this up for most of the day. Hope for an EOD run, and then news on Monday.
Posted by Johnwayne on :
Well earlier this morning I noticed the bid dropped to .023 while ask stayed at .0255. Usually if the bid drops and ask doesn't than it's mm's trying to shake some shares free!
Posted by ehya on :
Thats interesting, never thought of that.
Posted by ehya on :
Just wandering if anybody knows, how that affects this stock, and how it normally plays out once it is off this list?
Posted by Johnwayne on :
I'm no help to you there Ehya.
Posted by Johnwayne on :
OLMP, whoever that is, has sat on the bid almost the whole day. But typical Friday, the volume dried up.
Posted by Johnwayne on :
Pretty steady day. Typical Friday. Hope for a solid PR on Monday. Looks like these guys put quite a few PR'S out. Good luck to all!
Posted by JimSC on :
Ehya wrote:
see its still on the SHO list.
******** This means the MMs are still collecting the cheap shares. So, it may take a few more days for the run. We have to wait.
Posted by Johnwayne on :
What was the first date this was on SHO? It hs supposed to be off in two weeks right? Or is that a rule not followed?
Posted by Johnwayne on :
Hey guys - News is out!!! I don't know how to post links or anything but I saw it on Yahoo.
Posted by cottonjim on :
DNAPrint Genomics, Inc. (OTC BB: DNAG) today announced that research to develop commercial grade PT-401, a more powerful form of the anemia drug Erythropoietin (EPO), is proceeding on schedule with the manufacturing of PT-401 in mammalian cells being shown to be very efficient. Erythropoietin (EPO) has a worldwide market exceeding $11 billion and is growing at an average annual rate of 18% for the past 5 years. MarketWire. Is this the news you mean?
Posted by cottonjim on :
news out at 7am this morning.
Posted by JimSC on :
DNAG: great news and great chart. Watch it.
Posted by JimSC on :
DNAG will break out soon -- if the MMs decide to cover their shorts. Watch it.
Posted by JimSC on :
DNAG: Among last 10 trades - 10 buys vs. 0 sale. Strong uptrend. Watch it.
Posted by JimSC on :
DNAG: 0.0259 -- up 5.7%. Great Volume. Watch it.
Posted by Johnwayne on :
Jim- Any idea when this comes off SHO? Boy level 2 ask is so weak right now it would not take much pressure at all to shoot up to .03. I think mm's would stand aside and let her go if volume came in. Any idea what average volume (3month) is for this?
Posted by Johnwayne on :
Jim- You seem to know alot about MM's. What would make the MM's decide to cover their shorts? IS the decision strictly based on the number of shares they own?
Posted by JimSC on :
They tried to swing between 0.0238 to 0.0265 and shake out more shares. In the mean time if enough traders step in to get hold of some of the shares, the MMs will be forced to cover their short positions. If the volume continue to build up, the Mms will lose control and let her go. The chart and volume will attract more traders, which will, in turn, build up volume. This interaction will result in a big run. Just check the volume every day and wait for it to happen.
Posted by Johnwayne on :
Thaks for info Jim... I will answer my other question.... 3 month average volume is 6 million sometimes it makes sense to get off my duff and DD myself!
Posted by JimSC on :
DNAG: the pps has been pulled-down by a factor of 50.0 -- a huge rebounce is expected. The MMs' collecting phase is almost completed. They will gradually raise the pps to unload their inventory. Watch it.
Also do your DD for PMED.
Posted by Johnwayne on :
It would appear that OLMP is the big bully again today holding this down. Alot of buys went through at .0259 and he wouldn't budge. That was the turning point of this day.
Posted by djequipment on :
6) BC-LOH – Breast Cancer (DNAPrint/Moffitt) * R/D 2003… Diagnostic Phase I - 2004/08…FDA-PMA 3Q08…Launch 2009 * Market Potential - $400 Million Dollars
7) Xeliri/Xelox – Colon Cancer (DNAPrint/Moffitt) * R/D 2003… Diagnostic Phase I - 2005/08…FDA-PMA 4Q08…Launch 2009 * Market Potential - $200 Million Dollars
8) Diabetes – Pre-Diabetes and Diabetic Complications * R/D 2005... Diagnostic Phase I – 1Q06… FDA-PMA 1Q09…Launch 2010 * DNAPrint licensed diabetes diagnostics test from Harvard Medical School – Jan 26, 2006 * Market Potential - $5 Billion Dollars * New - Feb 14, 2006 - DNAPrint Pharmaceuticals Retains DOCRO for Development of Immunoassay to Better Detect Diabetic Vascular Complications. DOCRO will perform technical and clinical assistance and provide guidance on the regulatory requirements associated with the design of clinical trials necessary to commercialize DNAPrint's recently in-licensed intellectual property relating to glycated CD59. "DOCRO is a leading CRO specializing in the commercialization of diagnostic technologies," commented Dr. Hector J. Gomez, MD, PhD…"DOCRO's proven formula for success has resulted in an unparalleled track record at the FDA with over seventy consecutive successful FDA submissions."
Theranostics Products – Drug and Drug Test Combinations
9) PT-201 – Opthalmic Allergies * Phase II – 2Q06…FDA-NDA 4Q07…Launch 2008 * Market Potential - $50 Million Dollars
10) PT-202 – Nasal Allergies * Phase I – 2Q06…FDA-NDA 4Q07…Launch 2008 * Market Potential - $50 Million Dollars
11) PT-301 – Atopic Dermatitis * Phase I – 2Q06…FDA- NDA 2Q08…Launch 2009 * Market Potential - $600 Million Dollars
12) PT-401 - Super EPO Anemia Drug – Renal Failure * License Apr 2005…Pre-clinical 4thQ 2005/2006…FDA-NDA 2009…Launch 2010 * Market Potential - $2.5 Billion Dollars – Revised 3/14/06 - $11 Billion Dollars * DNAPrint exclusive worldwide license to develop a Super EPO anemia drug for renal failure * Consulting contract with Super EPO inventor/patent-holder to help DNAPrint develop Super EPO drug * Contract for CRO to manufacture Super EPO drug for pre-clinical testing, ready Fall 2005 (completed) * Sept 2005 – Super EPO drug begins pre-clinical testing. Production schedule remains on track * TWST – “We expect to file a New Drug Application (NDA) by 2009 and a product launch somewhere around 2010.” * New – Mar 14, 2006 – DNAPrint™ Genomics Pharmaceuticals Division Announces That Research on Development of Super EPO Drug for Anemia Market Shows Promising Early Results
13) PT-501 – ADHD - Methylphenidate – Ritalin-like Compounds * License Oct 2005….Pre-clinical 2005…FDA-NDA 2009…Launch 2010 * Market Potential - $4.6 Billion Dollars * Oct 25, 2005 -- DNAPrint genomics, Inc. today announced it has licensed a series of methylphenidate analogs or Ritalin(TM)-like compounds targeting the clinical development of enhanced pharmaceuticals for the treatment of drug addiction, attention deficit hyperactivity disorder (ADHD), and depression. This is the second drug project that will be developed by DNAPrint Pharmaceuticals. Inc., the Company's wholly owned, recently formed pharmaceutical subsidiary focused on personalized medicine….Ritalin(TM) or methylphenidate analogs represent a $4.6 billion dollar market opportunity by 2014, (Decision Resources, Inc)…. *Dr. Froimowitz and DNAPrint genomics are working with the National Institute for Drug Abuse (NIDA) in identifying compounds that offer potential relief to the craving usually associated with drug abuse. * TWST - Drug addiction compound has actually been selected by the National Institute of Drug Abuse (NIDA) for further study. * New – Mar 3, 2006 - DNAPrint announced that it has entered into a Research Sponsorship Agreement with the Massachusetts College of Pharmacy and Health Sciences for the potential development of Ritalin(TM)-like compounds as possible medications for drug abuse, attention deficit hyperactivity disorder (ADHD) and depression. “In fact, the National Institute of Drug Abuse has selected one of Dr. Froimowitz's compounds for their pre-clinical drug addiction development program. We will be supplying purified compounds to NIDA for further development."
14) PT-502 – Drug Addiction - Methylphenidate – Ritalin-like Compounds * License Oct 2005…. Pre-clinical 2005…FDA-NDA 2010…Launch 2011 * Market Potential - $500 Million Dollars
20) BF 200 ALA – Kondyloma – for epidermotropic human papillomavirus (HPV)…in Clinical Phase II…Market 2009
21) BF 200 ALA – VIN III – for vulvar intraepithelial neoplasia …in Clinical Phase II…Market 2009
22) 5-HT2B receptor antagonist - for migraine prophylaxis - in Preclinical 2005…Market ?
Other DNAPrint Studies
23) Immune System Deficiencies and Suppressants - Sirolimus, Tacrolimus, Mycophenolate * R/D 2001…NYU?…. Fall 2005 - Elipsis Biotherapeutics – Crohn’s Disease and other immune system disorders
24) Acute Lymphocyte Leukemia (ALL) * R/D 2005…Joint Publication late 2005….DNA Screening Test 2006?…..
25) Cervical Cancer and Environmental Tobacco Smoke * FAMRI Grant Feb 2003….2 year grant….Publication 2006?....
PARTNERS
* Forensics and Consumer Genealogy - Lynn Peavey, Orchid Biosciences, and ReliaGene Technologies * Forensics – DNAPrint working with defense industry consultant, Defense Life Sciences, towards defense and homeland security applications…Aug 2005
MERGERS, ACQUISITIONS, and SUBSIDIARIES
* DNAPrint Pharmaceuticals Subsidiary – DNAPrint Genomics forms wholly owned pharmaceutical subsidiary focused on personalized medicine, DNAPrint Pharmaceuticals…Oct 12, 2005 * "We are at the forefront in the development of personalized medicines and genomics-based pharmaceuticals, the Company's main focus," stated Hector J. Gomez, M.D., Ph.D., DNAPrint's Chairman and Chief Medical Officer, who will head the new subsidiary's day-to-day operations. "We believe that test/drug combinations called 'theranostics' are the wave of the future and that our new DNAPrint Pharmaceuticals subsidiary affirms the Company's commitment to the development of these products." Data Monitor and the Pharmaceutical Manufacturer's Association expect the worldwide pharmaceutical market to more than triple over the next 10-15 years to an estimated trillion dollars a year.
* DNAPrint ACQUISITION – Trace Genetics…Acquired Jun 2005 * Trace Genetics – diagnostics specialists in genetic identity DNA analysis, with expertise in genetic genealogy, forensics, molecular diagnostics and population genetics * Trace Genetics will do product testing, production, and sales for forensics and consumer genealogy while DNAPrint continues core drug discovery research and clinical trials for DNAPrint’s growing drug pipeline.
* DNAPrint ACQUISTION…Biofrontera AG…July 13, 2005 * DNAPrint Genomics Acquires 18% Interest In Biofrontera AG, a Small German Pharmaceutical Company * Biofrontera has proprietary programs for gene expression analysis and has 3 drugs already in their pipeline * Biofrontera just acquired a new drug (Sept 2005) and now has 4 drugs in their pipeline * Biofrontera milestone: Biofrontera stated intentions to do an IPO stock offering in Europe. * Sept 2005 – Biofrontera completes bond funding for $20 million euro. Biofrontera’s new IPO stock offering is on track within 9 months * Sept 2005 – Biofrontera acquires new drug for Atopic Dermatitis for it’s drug pipeline
* DNAPrint ACQUISITION – Kenna Technologies, Inc…Acquired Oct 25, 2005 Kenna Technologies, Inc., expertise in computational biology. Kenna is an in-silico drug discovery company developing proprietary biological simulations that will improve and accelerate drug discovery and development. Kenna’s platform provides a new rationale for selecting drug targets, evaluating the activity of candidate compounds, and planning clinical trials for promising drug compounds.
* DNAPrint ACQUISITION – Elipsis Biotherapeutic Corporation…Acquired Dec 22, 2005 SARASOTA, Fla., Dec. 22, 2005 -- DNAPrint Genomics, Inc. today announced the completion of its previously announced acquisition of Ellipsis Biotherapeutics Corporation, which will operate as a drug and diagnostic subsidiary. Ellipsis will retain its existing personnel and continue to be managed by Dr. Laurence Rubin, who is also the Director of the Division of Rheumatology at St. Michael's Hospital in Toronto. His research has focused on the genetic determinants of osteoporosis, rheumatoid arthritis and other inflammatory diseases. In addition, Ellipsis has acquired a diverse portfolio of genetic data and intellectual property from unique patient populations, specifically with Inflammatory Bowel Disease (Crohn's disease) including last year's publications of the discovery of a gene for Crohn's disease. Diagnostic applications are currently under development in this and related areas of autoimmune inflammatory disorders. * New – Feb 21, 2006 - Ellipsis Biotherapeutics Completes Four Contracts for High Through-Put Genotyping Services For Record Quarter Of Revenues
* New - DNAPrint - Research Sponsorship Agreement with Mass.College of Pharmacy and Health Sciences - 8-K Jan 31, 2006 On January 31, 2006, the Registrant entered into a Research Sponsorship Agreement with the Massachusetts College of Pharmacy and Health Sciences for sponsored research in connection with the synthesis and testing of certain (Ritalin) compounds as possible human medications for drug abuse, attention deficit hyperactivity disorder, and depression. The research will be conducted under the supervision of Dr. Mark Froimowitz. The Registrant had previously licensed exclusive rights to the compounds from Dr. Froimowitz on October 19, 2005 under an Exclusive Licensing Agreement. The sponsored research payments total $300,000 and will be paid in monthly installments of $25,000 over one (1) year. ---------
All drugs, projects, acquisitions, and other data listed in this DNAPrint pipeline may or may not be inclusive of all possible drugs, projects or acquisitions that DNAPrint may presently be involved in. Milestone dates are subject to change by DNAPrint Genomics.
** Note: All above information on DNAPrint's research, acquisitions, and drug products pipeline are all documented from DNAPrint’s newsletters, PR's, Analyst Reports, and SEC filings.
Of course, Do Your Own DD….and make your own best informed investment decisions.
Posted by Johnwayne on :
It's showing some spunk this morning. Up 8.8%
Posted by macdrsirules on :
Almost every single order has been a buy at the ask. Better keep a very close eye on this one or get in like I did.
Posted by Johnwayne on :
Here's the battle line for today boys. MM's have line drawn in the sand at .027 on ask.
Posted by macdrsirules on :
Yeah kinda funny when over 200k on 5 orders go through at .027 and suddenly the ask drops .0267. Not right.
Since 9:45 I can see 23 of 27 orders have been buys at the ask with 1 sell at bid and 3 in between.
Posted by Johnwayne on :
MM'e been doing that since I got in last week. Very few sells and still they keep the lid on it.
Posted by Johnwayne on :
MAC- Another solid start to day and looks like a pretty good shot to at least close at .026. 3mm's on bid at .026. Not much resistence left until .03. I would think we could start seeing some .03 buys early next week. Volume is a little light but not too bad. It keeps building a little more momentum each day.
Posted by JimSC on :
Great chart -- looks like the MMs are trying hard to hold her down, but her turn is coming soon. Watch it.
Posted by JimSC on :
DNAG got a great show today.
Posted by JimSC on :
DNAG: 0.0276, up 6% -- ready to fly.
Posted by JimSC on :
DNAG: MMs may let her fly tomorrow. Watch it.
Posted by djequipment on :
Heck yeah.
We have been sitting pretty with our 6% gains each day. I'll take it, that's for sure.
But I think the top is wound nice and tight and is getting ready to be cut loose. Friday's trading may be light, but if not look out. 03 is just around the corner!
Posted by macdrsirules on :
JIMSC, I think you are right. Tommorrow may be the start of a big run for DNAG. If it is not it will be soon. Buying pressure too strong.
Posted by JimSC on :
DNAG: I don't mind if the MMs hold her longer, as long as she gets to jump up 6% a day. The chart looks so perfect. Don't you think so?
Posted by Johnwayne on :
Jim- Awesome Day yesterday. Looks like the MM's are lining up to keep it under .003. But 1,000,000 volume already. We will need a huge volume day to break .003
Posted by superman7 on :
looking real good count me in for some Posted by JimSC on :
DNAG: 0.0298 -- up another 7% with good volume; great show for today. MMs might have a plan for her next week. Watch it.
Posted by Johnwayne on :
Superman 7- Welcome. Looking at level 2 I would say .003 is the line MM's have drawn in the sand so look for a little pull back here and then hopefully we'll be back up to try to hack through some of these asks (8 at .003). I got in at .00245 and haven't seen anything close to the volume we are seeing today (22 day average volume is 7million) so I don't really know what to expect today. Good Luck
Posted by superman7 on :
here we go baby!! breakout
Posted by JimSC on :
DNAG: FLY FLY Fly
0.034 -- up 20%.
Today is the day.
Posted by JimSC on :
Superman, your order may have triggered the run. LOL.
Posted by Johnwayne on :
Boy with this much volume I just don't know what to expect!!! Man look at her go! L2 looks like another fre wall set up at .0035 but heck I thought that at .003 too! Just when I'm starting to think I know something...
Posted by JimSC on :
DNAG: 0.03 to o.035 -- with great volume; may have muti-day run.
Posted by Johnwayne on :
Jim - I agree with multi day run scenario but I think we need news early next week and need to close .03 or higher with EOD run close to high of day!!!
Posted by Johnwayne on :
Dang it looks like they're gonna take it under .003.
Posted by JimSC on :
DNAG: 0.030 - up 8%; great volume; uptrend confirmed.
Posted by Johnwayne on :
Yes a close at .03!! I love it. What are you thinking for next week Jim? I'm thinking with news this will skyrocket. Your 400% in 4 weeks prediction is looking dead on right now. Volume was huge today and the good news is we spent all day chewing through millions of shares in the .03 range. Should soften that level up for next week!!! Do you think we need news for this to run or are you convinced we'll run regardless?
Posted by djequipment on :
I flipped this puppy once before from .02 to .04.
I flipped again on Friday from .023 to .032. I'll take the 30%-ish gain and put it in my pocket.
I am really liking this stock, I think it is one of the few pennies you can feel secure putting your money in and letting it sit overnight. I totally like where this comany seems to be heading. I'll watch Mondays action and jump back in with my initial investment and get ready to flip again.
I see green in DNAG's future!
Posted by Johnwayne on :
DJ- What do you expect on Monday? DNAG moves pretty solidly with news too. I think without news we will see a slight dip to just below .03. Then when news hits this puppy will fly straight to at least .035.
Posted by Johnwayne on :
Does any one have insight on Friday's press release? 35million dollar Financing agreement. I am concerned about this but don't know much about the financing end of things.
Posted by BuyTex on :
JW, post it, or a link, please...
Posted by djequipment on :
TEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
On March 13, 2006, the Registrant issued to Dutchess Private Equities Fund, L.P. ("Dutchess") a promissory note (the "Note") in the amount of $1,500,000 for a purchase price of $1,200,000.
As previously reported, on September 28, 2004, the Registrant entered into an Investment Agreement (the "Investment Agreement") with an affiliate of Dutchess, pursuant to which Dutchess has committed to purchase common stock of the Registrant up to an aggregate purchase price of $35 million over a two year period. The Dutchess Agreement provides that the Registrant from time to time may deliver a put notice to Dutchess, and Dutchess is obliged to purchase the dollar amount of common stock set forth in the notice.
The Note is due and payable in full on March 6, 2007. Other than the discount inherent in its purchase price, the Note is noninterest-bearing. The Note will be repaid using 100% of the proceeds of each put notice delivered by the Registrant to Dutchess under the Investment Agreement. The Note is also secured by a security interest in substantially all of the Registrant's assets pursuant to a Security Agreement dated October 21, 2005 with Dutchess.
In connection with the Note, the Registrant also paid Dutchess a facility fee of $65,000 and issued to Dutchess a non-interest bearing convertible debenture in the amount of $330,000 payable on March 6, 2011. The shares of common stock underlying the debenture carry piggyback registration rights. The debenture may be converted at Dutchess's option at a conversion price equal to $0.01 per share.
Posted by Johnwayne on :
Sounds like may be dillution
Posted by Johnwayne on :
No wait I'm confused here as usual... Dutchess will purchase $35M worth of common stock AND get CD's? So they purchase stock and then also convert CD's? Purchasing stock will raise the PPS thus letting them convert less shares? Why would they do both or would they convert first and than purchase?
Posted by Johnwayne on :
Good news- Bid building this morning... 3 *.0298 ask is thin until .035
Bad news- OLMP sitting on ask at .03.... not good to have OLMP on ask.
Posted by Johnwayne on :
Somethings shaking this morning boys ..... 855,000 pre-market all at .03 bid up to .0305 ask at .031
Let's watch and see if this is a head fake!! Hope not.
Posted by Johnwayne on :
Huge volume this morning but it looks like MM's don't want to let her go yet, thin but tightly bunched on the ask.
Posted by Johnwayne on :
OLMP is the story again today, selling into the run and volume has slowed tremendously. I have a hunch we will see some news tomorrow so should know for sure iif we see late day buying pick up.
Posted by Johnwayne on :
310,000 shares bought at .0307 in the last 45 minutes and OLMP won't budge off the ask.
Posted by Johnwayne on :
OLMP wins today. Constant dumping at .03 throughout today. Every buy today has been over .03 while the selling has been at .03 all day, killing every run. Too bad because Level 2 has looked ripe for a run to .035 all day.
Posted by djequipment on :
Well the MM's seemed to have gotten their shake today.
I hope to get back in at .026 tomorrow after selling at .032 last week. I think we will see .032 then .035 before long. And we know DNAG likes their press releases and volume has still been pretty darn strong.
Posted by djequipment on :
I bought back in today * .025.
Posted by macdrsirules on :
This .023 range has been support for a while. I hope we can bounce off it.
I like that we are still trading almost 5,000,000 shares on a slow day like this.
Posted by MillerTIME on :
Keep an eye out here. .0196x.02
Break of .02 will send it easily to .025. THis is easy money. HOld accumulate at bottom, sell at top at about 30-50% up. Good luck to all who get in.
Check out chart and do your DD. Way oversold and all indicators at bottom. No s8s or Sb2s out either.
Posted by MillerTIME on :
Good luck guys. LOL
.02 x .0205
Posted by AtHomeDad on :
Updated:2006-04-13 07:25:53 DNAPrint Genomics Ancestry Technology Highlighted in Article in the New York Times Market Wire
SARASOTA, FL -- (MARKET WIRE) -- 04/13/06 -- DNAPrint Genomics, Inc. (OTC BB: DNAG) today announced that the Company's technology was highlighted in an article entitled "Seeking Ancestry in DNA Ties Uncovered by Tests" in the April 12, 2006 edition of The New York Times.
The article reported that genetic tests, once obscure tools for scientists, have begun to influence everyday lives in many ways and that people are utilizing them when applying for jobs and college scholarships. "The tests are reshaping people's sense of themselves -- where they come from, why they behave as they do, what disease might be coming their way," The Times reported.
Commenting on the article following its publication, DNAPrint President and Chief Executive Officer Richard Gabriel said that there is a growing interest and demand for the Company's ANCESTRYbyDNA(TM) technology for determining family heritage. "In many instances, people who take the test want to determine whether they have American Indian or other ancestry to validate eligibility for college admission or scholarship programs. DNAPrint Genomics maintains the largest Native American DNA Database in North America."
In addition to its ANCESTRYbyDNA(TM) test for determining family heritage, DNAPrint Genomics' technology has forensic applications. The Company's DNAWITNESS(TM) product analyzes DNA taken from crime scenes, and has been utilized in more than 100 criminal investigations worldwide. DNAWITNESS(TM) test results have assisted investigators in many high profile criminal cases, including the apprehension and conviction of a serial killer in Louisiana.
Posted by ehya on :
Possibly some early reversal indicators. RSI comming off 30 and DI+ heading back up.
DNAPrint Genomics Receives Notice of Allowance for Patent for Identifying Links Between Gene Sequences and Medical Traits Sophisticated Technology Utilized by Company's DNAPrint Pharmaceuticals Subsidiary
SARASOTA, FL -- (MARKET WIRE) -- 04/20/2006 -- DNAPrint Genomics, Inc. (OTC BB: DNAG) today announced that the Company has received a Notice of Allowance from the U.S. Patent and Tradmark Office for a patent application, Methods for the Identification of Genetic Features for Complex Genetics Classifiers. The patent protects the Company's methods for identifying links between gene sequences and phenotypes (physical or medical traits).
"Gene sequences are highly polymorphic in the population, which means that they come in various forms or 'flavors,'" stated DNAPrint Genomics Founder and Chief Scientific Officer Tony N. Frudakis. "Polymorphism is usually measured at the level of the single nucleotide polymorphism (SNP) but our technology measures at the level of the haplotype (strings of SNPs), which provides researchers considerably more information. The methods covered in the patent allow for an efficient and powerful means for identifying haplotype."
The recent patent provides legal protection for DNAPrint's status as one of a very few companies currently capable of performing objective, assumption-free haplotype analyses. DNAPrint is also the only company currently using Ancestry Informative Markers (AIMs) and has patents pending in this area as well. Because of limitations with traditional genome screening methods and the complex genetic characteristics of modern populations, AIMS are integral to the development of DNA tests for the inference of genetic ancestry based on phenotypes, including identifying certain physical characteristics, or an individual's predisposition to respond to certain drugs.
"The Company is committed to developing a new class of drugs, called 'theranostics,' which are test+drug combinations designed to help ensure that patients receive the appropriate medicine and proper dosage based on their genetic constitution. The application of theranostics is also designed to increase efficacy and reduce side-effects," said DNAPrint Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D. "Our sophisticated genetics technology is playing a key role in the research and development of potential new drugs."
Highlighted Links MacReport.Net DNAPrint™ genomics, Inc.
"This patent cuts across a wide audience of developers from drug companies to people working on technology in the forensics and consumer areas," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "We plan to vigorously utilize and practice our patents and we will be reviewing the fields of genetic testing, drug development, forensic sciences and consumer products with our patent counsel to determine potential areas of development. We want to ensure that we extract the greatest economic value out of this patent for our shareholders and investors."
DNAPrint Genomics currently holds two patents and has several others pending or in the hands of patent counsel.
About DNAPrint Genomics, Inc.
DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS™, RETINOME™, ANCESTRYbyDNA™ and EURO-DNA™. DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Posted by AtHomeDad on :
Will a big Pharm ever buy DNAG, or will this fly on its own?
![[Smile]](smile.gif)